Research on Ivermectin

This study (as yet unpublished) study involved 60 patients with COVID-19 and severe pneumonia. These were randomized into 2 groups of 30. The study group received Ivermectin, HCQ, Favipiravir and Azithromycin. The control group did not receive Ivermectin but the other 3 medicines. The study ran from May to September 2020. In the group where Ivermectin was administered, 22 of the 30 patients improved within 10 days. In the control group, this was in 16 of the 30 people. 9 people died in the control group and 6 people in the intervention group. After 10 days, a PCR test was taken. Unfortunately, this only happened in 8 people in the control group and 16 in the intervention group. 3 subjects in the control group tested negative and 14 in the Ivermectin group tested negative. Okumus, N (2020) Ivermectin for Severe COVID-19 Management

Dr. Mobeen Syed provides an interesting and clear explanation of the mechanisms of action of Ivermectin. 25 min. Presentation on Youtube.

On Jan. 19, a new study published in a Lancet journal. This is a small double-blind randomized placebo study in 24 COVID-19 patients who visited the University Hospital of Navarra. 12 subjects received a single dose of Ivermectin at 400 mcg / kg. The 12 participants in the control group received a placebo. After 7 days, all participants still tested positive. There was, however, a faster viral clearance among the patients who received Ivermectin. They also had fewer complaints during recovery. Chaccour, C. et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

A preprint publication of a double-blind randomized placebo study has recently appeared. This is a research design that controls as much as possible for other variables. The study was conducted among 112 participants with mild to moderate COVID-19 symptoms. 55 participants received 12 mg of Ivermectin on days 1 and 2. 57 participants received a placebo. The results show no difference between the two groups in the percentage that test positive on day 6. It is striking that the test result of 32% of the participants is not known (for unclear reasons). Furthermore, no difference was discernible in the number of people leaving the hospital on day 10 and the percentage admitted to the ICU. What was also striking is that there was a difference between the number of patients that left the hospital on day 6 (11 in the IVM group vs. 3 in the placebo group). There was also a statically significantly lower death rate in the group using Ivermectin (0 vs. 4 deaths). Ravikirti, R. et al. Ivermectin as a potential treatment for mild to moderate COVID-19 - A double blind randomized placebo-controlled trial

On January 8, the research results of a study that investigated the preventive effect of Ivermectin among healthcare workers were announced (Chala 2020). In the Argentine province of Tucuman, a group of 234 healthy workers was examined in public health clinics between October and December. This group was split into two parts of 117. One group received treatment with Ivermectin and iota-carrageenan nasal spray. The other group received no treatment. In the treated group, 3.4% tested positive for SARS-CoV-2. In the no-treatment control group, 21.4% tested positive. The disadvantage of this study is that no placebo was used and that a nasal spray was also administered, so that the result is not unambiguously interpretable.

In Lagos, the Nigerian capital, research was conducted between May and November into the effect of Ivermectin in COVID-19 patients. The study involved 62 positively tested people with no or mild complaints. The group of 62 participants was split into three. They used different medications for two weeks. One group received a low dose of Ivermectin, another group received a higher dose and the third group received a different antiviral agent. In the group that did not use Ivermectin, it took an average of 9.15 days to test negative again. The group that received a low dose of Ivermectin was negative again in an average of 5.32 days. The group with the highest dose of Ivermectin took 4.62 days to test negative again. Almost twice as fast as the group without Ivermectin. No negative side effects have been reported with the use of Ivermectin. The preprint study was published on January 6. Babalola, O. et al. Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomized controlled double blind dose response study in Lagos.

A meta-analysis of 11 randomized studies (1452 subjects in total) into the use of Ivermectin in COVID-19 patients shows excellent results. Ivermectin helps in getting virus-free faster and in hospital stays shorter. In addition, it shortens the recovery time of sick patients by 43% and increases the survival rate by 83%. The preliminary results were presented by Dr. Andrew Hill. One of the researchers and associated with the University of Liverpool. There are currently 45 new clinical studies on the use of Ivermectin in COVID-19. More results are expected in the coming months. WHO is supporting this research as part of an ACT accelerator program to increase accessibility to COVID-19 treatments.

A major study into the preventive effect of Ivermectin has been carried out in four hospitals in Argentina. The survey was conducted among a large group of medical personnel. Of these, 708 used Ivermectin in addition to protective agents. Another group, consisting of 407 employees, only used protective agents. In the three months of the study, 237 of the 407 (58%) employees without Ivermectin tested positive for COVID-19. In the group where Ivermectin was used, no one tested positive for COVID-19. Carvallo, H. Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. Journal of Biomedical Research and Clinical Investigation, 2020; full. 2 (1) (preprint)

Ivermectin was investigated in the US state of Florida between March and May. It was investigated whether Ivermectin promoted the recovery of sick patients. A total of 280 patients participated in the study in four hospitals. Of these, 173 were treated with Ivermectin, while 107 patients received standard care. The mortality rate in the group of patients receiving Ivermectin was 15.0%. The group of patients with the standard treatment had a death rate of 25.2%. Among patients with severe pneumonia, the difference in mortality, using Ivermectin or standard treatment, was 38.8% versus 80.7%, respectively. Rajter, J. et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019. The ICON Study. CHEST, 2020; October

Last May, scabies, a parasitic infection, broke out in a French nursing home. As usual, a standard dose of Ivermectin was prescribed to the 67 elderly and the nursing staff. This had a surprising side effect. No one died of COVID-19 in the nursing home. 90% of the residents had an underlying condition and the mean age was 90 years. Researchers have made a comparison between the elderly and staff who used Ivermectin and those who did not. With Ivermectin 10.1% received COVID-19, without Ivermectin 22.6% received COVID-19. No one died in the medication group. Without medication, 4.9% died. Bernigaud, C. et al. Bénéfice de l'ivermectine: de la gale à la COVID-19, un exemple de sérendipité. Annales de Dermatologie et de Vénéréologie. 2020; full. 147 (12): A194